Drugs / Grass MATA MPL
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03931993 | Jan → Apr 2017 | seasonal allergic rhinitis | Allergy Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02557633 | Aug → Oct 2015 | allergic rhinitis | Allergy Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00104390 | Mar → Apr 2005 | hypersensitivity reaction disease | Allergy Therapeutics | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02582073 | Nov 2015 → May 2016 | seasonal allergic rhinitis | Allergy Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00133146 | Sep → Nov 2005 | hypersensitivity reaction disease | Allergy Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00133159 | Sep → Nov 2005 | IgE responsiveness, atopic | Allergy Therapeutics | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00414141 | Nov 2006 → Aug 2007 | IgE responsiveness, atopic | Allergy Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 16
| Date | Issuer | Release |
|---|---|---|
| 2026-02-26 | Allergy Therapeutics | Results Allergy Therapeutics presents progress at AAAAI allergytherapeutics.com ↗
Positive biomarker and clinical data demonstrating that Grass MATA MPL effectively induces tolerogenic properties through modulation of both humoral and cellular immune responses, with a statistically significant improvement of −22.5% in Combined Symptom Medication Score (P < 0.00004) compared to placebo across the G306 and G309 Phase III clinical trials |
| 2025-12-16 | Allergy Therapeutics | Regulatory Grassmuno® marketing authorisation in Germany allergytherapeutics.com ↗
Allergy Therapeutics granted marketing authorisation for Grassmuno ® (Grass MATA MPL) by the German regulatory authority, the Paul Ehrlich Institut |
| 2025-07-31 | Allergy Therapeutics | Results Grass MATA MPL Publications in Allergy Journal allergytherapeutics.com ↗
Grass MATA MPL was shown to be effective and well-tolerated in the G306 study |
| 2025-06-13 | Allergy Therapeutics | Results Allergy Therapeutics presents findings at EAACI allergytherapeutics.com ↗
Data showing a statistically significant, clinically relevant and consistent improvement in Rhinoconjunctivitis Quality of Life Questionnaire score and for all corresponding quality of life subdomains in patients with allergic rhinitis and/or rhinoconjunctivitis treated with Grass MATA MPL, the Group's short-course |
| 2025-02-27 | Allergy Therapeutics | Results Presentations at 2025 AAAAI / WAO Joint Congress allergytherapeutics.com ↗
A positive comparative assessment highlighting the efficacy of the pivotal Phase III trial with Grass MATA MPL, the Group's short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen |
| 2025-02-17 | Allergy Therapeutics | Results Grass MATA MPL Phase III data published in Allergy allergytherapeutics.com ↗
The successful G306 Phase III trial, which completed in November 2023 , met its primary endpoint, demonstrating a highly statistically significant reduction in the Combined Symptom & Medication Score (CSMS) of 20.3% (p=0.0005) compared to placebo over the peak pollen season. |
| 2024-11-25 | Allergy Therapeutics | Regulatory Submission of MAA for Grass MATA MPL allergytherapeutics.com ↗ |
| 2024-07-22 | Allergy Therapeutics | Results Trading update for the year ended 30 June 2024 allergytherapeutics.com ↗
Pivotal Phase III Grass MATA MPL trial (G306) successfully meets primary endpoint and positive discussions with regulators on pathway to marketing authorization application (MAA) submission |
| 2024-05-31 | Allergy Therapeutics | Results Allergy Therapeutics presents findings at EAACI allergytherapeutics.com ↗
The trial successfully met its primary endpoint, as previously announced on 14 November 2023. |
| 2024-05-07 | Allergy Therapeutics | Results Further detail from G306 Phase III field trial allergytherapeutics.com ↗
The trial successfully met its primary endpoint as previously announced on 14 November 2023. |
| 2023-12-13 | Allergy Therapeutics | Results G306 Phase III trial meets key endpoints allergytherapeutics.com ↗
As previously communicated, the active treatment group demonstrated a highly statistically significant reduction in Combined Symptom & Medication Score (CSMS) (p?0.0024) compared to placebo over the peak pollen season. |
| 2023-11-14 | Allergy Therapeutics | Results G306 Grass Phase III trial meets primary endpoint allergytherapeutics.com ↗
The trial met its primary endpoint demonstrating statistically significant superiority of Grass MATA MPL compared to placebo ( p ?0.0024, one-sided) in the CSMS during the peak pollen season, and the study was stopped for success. |
| 2022-04-25 | Allergy Therapeutics | Results Allergy Therapeutics shares data at WAO-BSACI allergytherapeutics.com ↗
Data from the study, conducted in the US and EU, show that the immunotherapy demonstrated clinically relevant and statistically significant reductions in the daily symptoms and the use of relief medications after 6 subcutaneous allergen-specific immunotherapy (SCIT) injections in two different treatment regimens. |
| 2022-03-01 | Allergy Therapeutics | Results Allergy Therapeutics shares positive new data allergytherapeutics.com ↗
Data show clinically meaningful and statistically significant reductions in symptoms due to grass pollen allergy and in the use of relief medications after six SCIT injections with Grass MATA MPL during peak grass pollen season |
| 2020-07-09 | Allergy Therapeutics | Results Invalidation of Birch MATA MPL phase III results allergytherapeutics.com ↗
Further to the announcement on 18 March 2019 and following extensive data investigations and discussions with PEI, the analysis of the primary endpoint of the Birch B301 clinical trial has been declared invalid. |
| 2018-05-21 | Allergy Therapeutics | Results Positive top-line results from Grass Ph II study allergytherapeutics.com ↗
The trial met its primary endpoint of establishing a dose-response relationship and a Phase III dose. |
All press releases naming this drug 19 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GrassMATAMPL | “GrassMATAMPL has been developed to provide pre-seasonal specific immunotherapy for patients with an allergy to grass pollen (hay fever).” NCT00133159 ↗ |
| Modality | Vaccine | “Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine” NCT00133146 ↗ |
| Route | Subcutaneous | “three 0.5 mL subcutaneous injections” NCT00133146 ↗ |